UBS Group
NGEN

UBS Group’s NervGen Pharma NGEN Stock Holding History

UBS Group’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$232K Buy
+61,517
New +$266K ﹤0.01% 6550

Other funds holding NGEN

PI
PFG Investments Woodbury, New York $2.15B AUM 25.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
VFIC
Valley Forge Investment Consultants Audubon, Pennsylvania $334M AUM 17.84% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

UBS Group's NGEN Position: Q1 2026 in Review

UBS Group opened a new position in NervGen Pharma (NGEN) in Q1 2026: 61,517 shares worth $232K. The stake represents ﹤0.01% of the portfolio and ranks #6550 among its holdings.

45 funds tracked by Wall St. Rank hold NGEN as of Q1 2026.

  • UBS Group held 61,517 shares of NervGen Pharma worth $232K as of Q1 2026.
  • NervGen Pharma was a new UBS Group position in Q1 2026.
  • NervGen Pharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6550 holding.
  • 45 funds tracked by Wall St. Rank held NervGen Pharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.